Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
204.82
+0.62 (+0.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024
January 03, 2024
These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky.
Via
The Motley Fool
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
January 02, 2024
Biotech stocks targeting longevity could uncover the fountain of youth in coming years, offering a prime investment opportunity today.
Via
InvestorPlace
Government-granted Patent Monopolies Are Not The Free Market
December 29, 2023
Our system for developing new drugs is a disaster. While we can point to great successes, they come at enormous cost. We will spend over $600B this year on prescription and non-prescription drugs -...
Via
Talk Markets
Topics
Intellectual Property
Exposures
Intellectual Property
Understanding Biogen's Position In Biotechnology Industry Compared To Competitors
December 27, 2023
Via
Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $800 Today
December 26, 2023
Via
Benzinga
Looking Into Biogen's Recent Short Interest
December 21, 2023
Via
Benzinga
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
December 29, 2023
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Via
Benzinga
Healthcare Heroes: 3 Stocks Innovating in Medicine and Wellness
December 27, 2023
Discover these innovative healthcare stocks, backed by the U.S.'s $4.3 trillion health investment, offering stability and high returns.
Via
InvestorPlace
Top 3 Healthcare Stock Picks for the New Year
December 25, 2023
Buy these healthcare stocks for 2024 trading at bargain prices before their earnings inflect higher on improving fundamentals.
Via
InvestorPlace
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
December 14, 2023
The increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight.
Via
InvestorPlace
Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry
December 13, 2023
Via
Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,200 Today
December 11, 2023
Via
Benzinga
The Latest Analyst Ratings for Biogen
December 07, 2023
Via
Benzinga
Comparative Study: Biogen And Industry Competitors In Biotechnology Industry
November 28, 2023
Via
Benzinga
Tuesday Talk: CPI Data And FOMC Meeting Hold Back Market Breakout
December 12, 2023
While the market continues towards making new highs, it is falling short of making a breakout rally. Forthcoming CPI data and the upcoming FOMC meeting may be the catalyst for same.
Via
Talk Markets
Biotech Is Coming Back, Can The Run Last?
December 11, 2023
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally.
Via
Talk Markets
2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond
December 09, 2023
These stocks aren't worth the risk.
Via
The Motley Fool
S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets
December 07, 2023
Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%).
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Here's How Much $1000 Invested In Biogen 20 Years Ago Would Be Worth Today
November 16, 2023
Via
Benzinga
Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry
November 14, 2023
Via
Benzinga
Why This Biogen Analyst Is Turning Bullish On Alzheimer's Treatment Prospects
December 07, 2023
Biogen Inc (NASDAQ: BIIB) has been in focus due to its treatment for early-stage Alzheimer’s disease.
Via
Benzinga
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
November 21, 2023
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this
Via
Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
November 17, 2023
Biotech companies are edging closer to finding the answers behind Alzheimer's disease.
Via
Investor's Business Daily
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
November 10, 2023
The major indexes ended long win streaks. Datadog led earnings winners.
Via
Investor's Business Daily
Expert Ratings for Biogen
November 09, 2023
Via
Benzinga
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
November 10, 2023
The real competitive battle is about to begin, and it will last a long time.
Via
The Motley Fool
These Analysts Revise Their Forecasts On Biogen After Q3 Results
November 09, 2023
Biogen Inc (NASDAQ: BIIB) reported better-than-expected third-quarter earnings.
Via
Benzinga
Thoughts For Thursday: Staying On Top - Barely
November 09, 2023
The stock market continues to be full of worry, but is managing to stay on top this week, so far. It is worth noting that yesterday's close brought levels back to those of a month ago.
Via
Talk Markets
Biogen (BIIB) Q3 2023 Earnings Call Transcript
November 08, 2023
BIIB earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.